Wilms tumor 1 gene, CD97, and the emerging biogenetic profile of glioblastoma

WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma

(2014) Julian Rauscher et al.   JOURNAL OF CLINICAL PATHOLOGY

Glioblastoma and Other Malignant Gliomas

(2013) Antonio Omuro   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Overexpression of CD97 Confers an Invasive Phenotype in Glioblastoma Cells and Is Associated with Decreased Survival of Glioblastoma Patients

(2013) Michael Safaee et al.   PLoS One

Expression and roles of Wilms' tumor 1-associating protein in glioblastoma

(2012) Du-Il Jin et al.   CANCER SCIENCE

Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness

(2012) Archana Chidambaram et al.   JOURNAL OF NEUROSURGERY

Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients

(2010) Yasuyoshi Chiba et al.   Brain Tumor Pathology

Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways

(2010) R T Sitaram et al.   BRITISH JOURNAL OF CANCER

Wilms’ tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression

(2010) Mike Y. Chen et al.   JOURNAL OF NEURO-ONCOLOGY

Effect of WT1 gene silencing on the tumorigenicity of human glioblastoma multiforme cells

(2009) Aaron J. Clark et al.   JOURNAL OF NEUROSURGERY

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme

(2008) Shuichi Izumoto et al.   JOURNAL OF NEUROSURGERY